Compare BCG & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | AYTU |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | 150 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 27.4M |
| IPO Year | N/A | 2015 |
| Metric | BCG | AYTU |
|---|---|---|
| Price | $1.69 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 80.2K | 46.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $1.36 | $1.46 |
| 52 Week High | $3.44 | $3.07 |
| Indicator | BCG | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 22.11 |
| Support Level | $1.46 | $1.85 |
| Resistance Level | $1.90 | $2.64 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 5.62 | 4.62 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.